La Mirada, CA, July 30, 2014 --(PR.com
)-- DNP International Co., Inc. (“DNP”) announced today that, effective immediately, DNP will exit the beta-alanine business. DNP and its affiliates will no longer import, export, supply, make, use, distribute, offer for sale, sell or supply beta-alanine, or any salt, ester, amide or derivative of beta-alanine.
DNP also said that it had resolved its disputes with Natural Alternatives International, Inc. (“NAI”) and Compound Solutions, Inc. (“CSI”) regarding its beta-alanine business. NAI owns a series of patents related to beta-alanine and CSI is NAI’s licensed distributor. In September 2011, NAI and CSI sued DNP for unfair competition in Delaware federal court. In December 2011, DNP asked that court to declare three NAI patents related to beta-alanine invalid. DNP filed a new case in January 2012 seeking a declaration that NAI’s U.S. Patent No. 8,067,381 (“the ‘381 patent”), also related to beta-alanine was invalid. NAI counterclaimed against DNP for infringement of the ‘381 patent. The parties have agreed to dismiss all claims and counterclaims with prejudice and that the ‘381 patent has not been found invalid by a final decision of any court or the U.S. Patent and Trademark Office.